Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.48 |
| ▸ | NFATC1 | O95644 | 3/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132970 | 1.00 | DYRK1A (0.48) | DYRK1ANFATC1GSK3BPDPK1TGFBR1 | |
| SCHEMBL30132971 | 1.00 | DYRK1A (0.48) | DYRK1ANFATC1GSK3BPDPK1TGFBR1 | |
| SCHEMBL25421426 | 0.82 | DYRK1A (0.51) | DYRK1ANFATC1GSK3BKCNH2 | |
| SCHEMBL21224289 | 0.82 | BRD4 (0.40) | DYRK1ANFATC1GSK3BTGFBR1 | |
| SCHEMBL16008957 | 0.80 | ELANE (0.36) | DYRK1ANFATC1GSK3BFFAR1 | |
| SCHEMBL44373 | 0.78 | GPR84 (0.43) | GSK3B | |
| SCHEMBL29544265 | 0.78 | GPR84 (0.43) | GSK3B | |
| SCHEMBL29801156 | 0.78 | DYRK1A (0.55) | DYRK1ANFATC1GSK3BDYRK1BKCNH2 | |
| SCHEMBL14857683 | 0.78 | DYRK1A (0.55) | DYRK1ANFATC1GSK3BDYRK1BKCNH2 | |
| SCHEMBL25421891 | 0.76 | DYRK1A (0.57) | DYRK1ANFATC1GSK3BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| CN-113993870-B | Imidazo pyrimidine compound containing fused ring group, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023280283-A1 | COMPOUND USED AS SHP2 INHIBITOR AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| WO-2021144439-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MERCK SHARPE & DOHME CORP. | 2015-11-26 | — | — | US | disclosed |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MERCK SHARPE & DOHME CORP. | 2015-11-26 | — | — | US | disclosed |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MERCK SHARPE & DOHME CORP. | 2015-11-26 | — | — | US | disclosed |
| EP-2855477-A1 | ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013181075-A1 | ISOTOPICALLY LABELED BIARYL UREA COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | DYRK1A 2507/4885NFATC1 2077/4885GSK3B 2542/4885 |
| US-20150336948-A1 | Isotopically Labeled Biaryl Urea Compounds | MAPT, SLC14A1, UBTF | DYRK1A 2261/4885NFATC1 3349/4885GSK3B 226/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | DYRK1A 2/4885NFATC1 2185/4885GSK3B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.